Concentrix Corporation is set to report its Q1 2026 earnings on March 24, with analysts expecting earnings per share (EPS) of $2.65 and revenue of $2.49 billion. While EPS is forecasted to slightly decline from $2.79 last year, revenue is projected to increase from $2.37 billion, indicating positive business growth. The company offers an attractive annual dividend yield of 4.68%, appealing to income-focused investors. Financial metrics show moderate valuation and reasonable liquidity, though the company carries significant debt relative to equity. Investors are optimistic following Concentrix's strong Q4 2025 performance and potential dividend income.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...
The global hybrid robots market is projected to grow from $5.68 billion in 2026 to $10.03 billion by 2030, with a CAGR of 15.3%. Growth is fueled by advances in AI, autonomous operations, and smart manufacturing, alongside rising demand for robots in...
